Lobe Sciences Ltd. and Cynaptec Pharmaceuticals to Present New Cluster Headache Therapy

Vancouver-based Lobe Sciences Ltd., in collaboration with Cynaptec Pharmaceuticals, announces its participation in the Clusterbusters 20th Annual U.S. Patient Conference. The event will occur from September 11-14, 2025, in Grapevine, Texas. This conference is a pivotal meeting for the cluster headache community, providing education and support.

Lobe Sciences will present their research on Conjugated Psilocin, a promising treatment for chronic cluster headaches. Dr. Fred D. Sancilio, Chairman and CEO, will discuss ongoing studies conducted by Cynaptec Pharmaceuticals with the compound L-130. Recently, Lobe secured $6M in funding to support FDA submission efforts for L-130, with potential for an additional $20M.

The conference offers a platform for Lobe to engage with patients and gather insights to design effective clinical trials. Their engagement demonstrates a commitment to innovative therapies for underrepresented conditions.